Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: J Nucl Med. 2008 May 15;49(6):978–986. doi: 10.2967/jnumed.107.048546

Figure 2.

Figure 2

(A) Saturation binding curve with inset Scatchard plot of radioligand receptor binding studies performed with 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative on MCF-7 human breast adenocarcinoma cells. The 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative showed a Kd of 11.0 ± 1.5 nM and Bmax of 1.3 ± 0.1 × 104 sites/cell. (B) Competition binding curve from radioligand receptor binding studies performed with the 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative as the radiotracer and the corresponding non-radioactive Re-labeled derivative as competitior using MCF-7 cells. The non-radioactive Re-estradiol-pyridin-2-yl hydrazine derivative yielded an IC50 of 15.0 ± 1.5 nM and a calculated Ki of 10.3 nM. Values were determined from three independent experiments.